Organisation paid for research Program year 2022 Source: CMS Open Payments

Triple O Medical Services

Neither a doctor nor a teaching hospital

Research payments

$2,438,280

81 payments

Through program year 2022, Triple O Medical Services is reported as receiving $2,438,280 in research payments, across 81 payments.

By program year

3 rows
Year Kind Amount Payments
2022 Research $85,153 10
2021 Research $1,504,070 48
2020 Research $849,057 23

Breakdown

Who paid Research payments · program years 2020–2022
  1. Regeneron Pharmaceuticals, Inc. $2,313,677 69 payments
  2. ViiV Healthcare Company $92,127 8 payments
  3. AbbVie, Inc. $32,475 4 payments
Studies the money was for Research payments · program years 2020–2022
  1. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $1,758,873 34 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $366,377 21 payments
  3. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $175,078 9 payments
  4. A Phase III, Randomized, Multicenter, Open-Label, Non-Inferiority Stud $56,132 2 payments
  5. A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $25,759 1 payment
  6. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1) $21,106 1 payment
  7. A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe Disease $13,350 5 payments
  8. A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ABBV-382 in Persons Living With HIV-1 (PLWH) $9,600 1 payment
  9. A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, No $7,434 4 payments
  10. A Multi-Arm, Phase 3, Randomized, Placebo Controlled, Double Blind Cli $2,802 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record